VolitionRx Limited (NYSE American: VNRX) has announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company says is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). This breakthrough addresses a longstanding challenge in liquid biopsy: separating cancer-derived DNA from the overwhelming background of healthy cell-free DNA. By generating highly enriched tumor DNA datasets, the technology could significantly enhance cancer detection and monitoring capabilities.
The publication describes a two-step process that combines physical sample enrichment with bioinformatic filtering to produce ctDNA sequencing datasets with greater than 99% purity. Early validation studies have demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have produced encouraging findings, suggesting the technology's potential clinical utility.
Volition is now advancing larger validation studies, collaborating with oncology key opinion leaders, and expanding patent protection for the technology as it explores commercialization opportunities. The company is conducting technical evaluations with potential licensing partners and estimates that the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications.
This development is significant because liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, potentially enabling earlier cancer detection and more effective treatment monitoring. The ability to isolate ultra-pure ctDNA could improve the sensitivity and specificity of liquid biopsy tests, leading to better patient outcomes. The large addressable market underscores the commercial potential of this technology, which could disrupt the current cancer diagnostics landscape.
Volition is a multinational company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For more information, visit the company's website at https://volition.com/. To view the full press release, visit https://ibn.fm/nuJEs.
